- The share
- Press releases
- Financial calendar
- Financial reports
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Thank you
XVIVO Perfusion advances the date for submission of the January-March 2020 interim report
In order to provide information on XVIVO Perfusion's results and financial position for the period January-March 2020 as soon as possible, the company has decided to advance the submission of the report. New report date is Thursday 9 April at. 7.30 a.m. A conference call will be held on Thursday, April 9 at. 11.30 a.m.
March 25, 2020
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 735 192159, email@example.com
Magnus Nilsson, CEO, +46 31 788 2150, firstname.lastname@example.org
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 am CET on March 25, 2020.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.